<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03536754</url>
  </required_header>
  <id_info>
    <org_study_id>CL011_140</org_study_id>
    <secondary_id>LUMINA-1</secondary_id>
    <nct_id>NCT03536754</nct_id>
  </id_info>
  <brief_title>A Study of CCX140-B in Subjects With FSGS</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Focal Segmental Glomerulosclerosis (FSGS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ChemoCentryx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ChemoCentryx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate
      the Safety and Efficacy of CCX140-B in Subjects with FSGS to be conducted in the North
      America, Europe and Australia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate
      the Safety and Efficacy of CCX140-B in Subjects with Focal Segmental Glomerulosclerosis
      (FSGS) to be conducted in the North America, Europe and Australia. The aim of this study is
      to evaluate the effect of treatment with CCX140-B, a selective antagonist of C-C chemokine
      receptor type 2 in subjects with focal segmental glomerulosclerosis on urinary protein
      excretion as assessed by changes in urine protein to creatinine ratio (UPCR)
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Randomized, placebo-controlled, Phase 2</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in urine protein to creatinine ratio (UPCR)</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Effect of CCX140-B on treatment of urinary protein excretion in subjects with FSGS as assessed by changes from baseline in UPCR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in renal function as assessed by changes in eGFR using several equations (see description)</measure>
    <time_frame>Baseline to weeks 12 and 24</time_frame>
    <description>Effect of CCX140-B on renal function as assessed by eGFR using the CKD-EPI Cystatin C, CKD-EPI creatinine equation, CKD-EPI creatinine-cystatin c equation and NDRD creatinine equation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in PK profile as measured by Auc0-6 at steady state at intervals throughout the treatment period</measure>
    <time_frame>Baseline to weeks 12 and 24</time_frame>
    <description>Effect of CCX140-B on the PK profile in subjects with FSGS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in PK profile as measured by Cmin at intervals throughout the treatment period</measure>
    <time_frame>Baseline to weeks 12 and 24</time_frame>
    <description>Evaluation of the PK profile of CCX140-B in subjects with FSGS</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>FSGS</condition>
  <condition>Focal Segmental Glomerulosclerosis</condition>
  <condition>Glomerulosclerosis</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (N=10)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CCX140-B 5 mg once daily (N=10)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CCX140-B 10 mg twice daily (N=10)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CCX140-B 15 mg twice daily (N=10)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>CCX140-B Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CCX140-B</intervention_name>
    <description>CCX140-B is an orally administered selective antagonist of CCR2</description>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects aged 18-75

          2. UPCR ≥ 1 g protein/g creatinine (or at 113 mg.mmol) at screening

          3. Diagnosis of FSGS based on renal biopsy or high risk genetic variant

          4. Diagnosis of one of primary FSGS based on characteristic histopathology, medical
             history and clinical course or FSGS secondary to genetic variants associated with
             increased risk or severity.

          5. Estimated glomerular filtration rate (eGFR) &gt;30 mL/min/1.73m2

          6. Clinical stable blood pressure not to exceed 145/95 mmHg

          7. RAAS blockers must be stable for at least 4 weeks prior to screening and projected to
             remain stable through week 12, unless adjustments are required for management of
             hypertension.

          8. Immunosuppressive or immunomodulatory therapy must be stable for at least 4 weeks
             prior to screening and projected to remain stable through study week 12

          9. Glucocorticoids must be stable for at least 4 weeks prior to screening and projected
             to remain stable through study week 12.

         10. Both genders of childbearing potential must agree to use adequate contraception during
             and for at least 3 months after the last dose of study drug.

         11. Subjects must be willing and able to give written Informed Consent and to comply with
             protocol requirements.

         12. Subjects must be judged to be otherwise fit for the study by the Investigator. -

        Exclusion Criteria:

          1. Pregnant or nursing

          2. History of organ transplantation

          3. On an organ transplant waiting list or anticipated organ transplant within 6 months of
             screening

          4. Anti-CD20 monoclonal antibodies within 20 months of screening are exclusionary.
             Subjects that used anti CD20 monoclonal antibodies prior to week 20 are allowed with
             confirmed recovery of CD20+ B cell population to within normal range

          5. Plasmapheresis within 12 weeks of screening

          6. BMI ≥40

          7. Participation in any clinical study of an investigational product within 12 weeks or 5
             half-lives of screening

          8. Currently on dialysis or likely to require dialysis during the blinded treatment phase
             of the study.

          9. History or presence of any form of cancer within 5 years of screening except excised
             basal cell or squamous cell carcinoma or carcinoma in situ such as cervical or breast
             carcinoma in situ that has been excised or completed resected without evidence or
             recurrence.

         10. Positive HBV, HCV, or HIV viral screening test. Subjects who have received highly
             effective therapy for HCV demonstrated to have negative viral titers for at least 6
             months following discontinuation of treatment, will be considered to have a negative
             HCV screening test

         11. Renal disease associated with disorders other than FSGS that is active or has
             significant risk of progressing during the course of the study.

         12. Disorders that are associated with FSGS lesions.

         13. Evidence of tuberculosis.

         14. Evidence of hepatic disease with the exception that isolated INR elevation in the
             absence of other significant liver enzyme abnormalities is explained by anticoagulant
             therapy, (e.g. warfarin)

         15. Hematologic abnormalities as follows: Hb &lt;8 g/dL, platelets &lt;50,000, ANC &lt;1000
             cells/µL) at baseline.

         16. QTcF greater than 450 msec.

         17. History of alcohol or illicit drug abuse or of lithium, pamidronate and interferon.
             Recreational use of cannabis is not excluded where legal.

         18. History of gastrointestinal conditions that may interfere with study medication
             compliance.

         19. Known hypersensitivity to CCX140-B or inactive ingredients of the CCX140-B tablets
             (including microcrystalline cellulose, starch, crospovidone, magnesium stearate, or
             silicon dioxide).

         20. History or presence of systemic disorder other than FSGS that requires, or is expected
             to require, systemic glucocorticoids or immune modulators during the study; topical or
             inhaled glucocorticoids and immune modulators are not excluded.

         21. History or presence of any medical condition or disease which, in the opinion of the
             Investigator, may place the subject at unacceptable risk for study participation.

         22. Subjects taking strong CYP3A4 inducers or strong CYP3A4 inhibitors within two weeks
             prior to screening.

         23. Subjects taking lithium or interferon; subjects taking non-steroidal anti-inflammatory
             agents (NSAIDS) chronically (intermittent, i.e. occasional NSAIDS for pain or fever is
             discouraged, but is not excluded).

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Staehr, MD</last_name>
    <role>Study Director</role>
    <affiliation>ChemoCentryx</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AKDHC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Los Angeles Biomedical Research Institute</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Louisiana Nephrology</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MGH</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Sciences Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Kidney Research Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Josephs Healthcare - Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre (Odette Cancer Center)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CISSS de la Monteregie-Centre - Hopital Charles LeMoyne</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux- Hospital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble cedex 9</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHM - Hopital de la Conception</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Prives de Metz</name>
      <address>
        <city>Metz</city>
        <zip>57045</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Azienda Ospedaliera Universitaria San Martino IST</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero di Montichiari-A.O. Spedali Civili di Brescia</name>
      <address>
        <city>Montichiari</city>
        <zip>25018</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione S. Maugeri IRCCS</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli - Universita Cattolica del Sacro Cuore</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Hospital</name>
      <address>
        <city>Takapuna</city>
        <state>Auckland</state>
        <zip>0622</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taranaki Base Hospital</name>
      <address>
        <city>New Plymouth</city>
        <zip>4310</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny w Bialymstoku - II Klinika Nefrologii z Oddzialem Leczenia Nadcisnienia Tetniczego i Pododdzialem Dializoterapii</name>
      <address>
        <city>Białystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCM Sp. Zo.o.</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny Klinika Nefrologii i Medycyny Transplantacyjnej</name>
      <address>
        <city>Wrocław</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zaklad Opieki Zdrowotnez Centralny Szpital</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge University - Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0OQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Foundation Trust Manchester</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morriston Hospital</name>
      <address>
        <city>Swansea</city>
        <zip>SA6 6NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 28, 2018</study_first_submitted>
  <study_first_submitted_qc>May 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2018</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulosclerosis, Focal Segmental</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

